Facebook Instagram Twitter Linkedin
Respira
A brand new assisted inhalation device
Read More
increasing compliance and effectiveness of spray drugs
Read More
generating precious medical data about patient's behaviours
Read More

GET IN TOUCH

ABOUT US

Respira is a startup company that is developing new solutions to assist patients in administering and monitoring their therapies.

The project team is composed of professionals with several different backgrounds and a specific focus on pharma solutions.

The company is currently preparing the product development phase intending to launch the product within 24 months and quickly gain a relevant market share in both Europe and the United States.

OUR MISSION

Improve the health of persons who have respiratory diseases such as asthma and COPD

Read More

OUR VISION

Enhance compliance and well-being of people generating substantial savings for healthcare systems

Read More

DEVICE AND MEDICAL DATA

Respira's Assisted Inhalation Device

Learn More

Respira's Medical Data

Learn More

TEAM MEMBERS AND BUSINESS PARTNERS

Alessandro

Dr. Alessandro Guglietta

Founder
Read More
Fabio

Dr. Fabio Penzo

General Advisor
Read More
Filippo

Dr. Filippo Fassio

Medical Advisor
Read More

RECENT NEWS

Respira's company creation

September 16, 2022

Respira has been officially incorporated as a company under Italian law.

Participation in "Patent+" tender​

September 19, 2022

The company presented a plan to enhance its patent worth 220,000 euros.

In vitro study at Parma University​

October 3, 2022

In collaboration with the University of Parma, the company conducted an in vitro study about its current prototype.

ABOUT US

Respira is a startup company that is developing new solutions to assist patients in administering and monitoring their therapies.

The project team is composed of professionals with several different backgrounds and a specific focus on pharma solutions.

The company is currently preparing the product development phase intending to launch the product within 24 months and quickly gain a relevant market share in both Europe and the United States.

GET IN TOUCH

CONTACT US

© Copyright 2022 - All Rights Reserved Designed by Azeem

Facebook Instagram Twitter Linkedin

A brand new Assisted Inhalation Device

The device looks like a shell in which the user places a pre-dosed spray inhaler (pMDI) obtaining immediate automation at the breath: when he inhales through the mouthpiece the device detects his inspiratory act, and it instantly delivers an optimized dose of a drug through an electromechanical compression system if they can. This compression technology ensures that the medicine is completely vaporized at the peak of the patient’s inspiratory flow, boosting the drug’s pulmonary deposition.

The device looks like a shell in which the user places a pre-dosed spray inhaler (pMDI) obtaining immediate automation at the breath: when he inhales through the mouthpiece the device detects his inspiratory act, and it instantly delivers an optimized dose of a drug through an electromechanical compression system if they can. This compression technology ensures that the medicine is completely vaporized at the peak of the patient’s inspiratory flow, boosting the drug’s pulmonary deposition.

Home Facebook Instagram Linkedin

A brand new Assisted Inhalation Device

The device looks like a shell in which the user places a pre-dosed spray inhaler (pMDI) obtaining immediate automation at the breath: when he inhales through the mouthpiece the device detects his inspiratory act, and it instantly delivers an optimized dose of a drug through an electromechanical compression system if they can. This compression technology ensures that the medicine is completely vaporized at the peak of the patient’s inspiratory flow, boosting the drug’s pulmonary deposition.

The device looks like a shell in which the user places a pre-dosed spray inhaler (pMDI) obtaining immediate automation at the breath: when he inhales through the mouthpiece the device detects his inspiratory act, and it instantly delivers an optimized dose of a drug through an electromechanical compression system if they can. This compression technology ensures that the medicine is completely vaporized at the peak of the patient’s inspiratory flow, boosting the drug’s pulmonary deposition.

Home Facebook Instagram Linkedin

Respira's device increases compliance and effectiveness of any spray drug

A preliminary “in-vitro” study has certified that the device optimizes drug administration by generating a measurable positive effect on deposition in the distal parts of the lung-simulating impactor.

We want to become the ideal partner for patients, doctors, and healthcare systems improving therapeutic adherence by producing a relevant increase in patients’ quality of life and generating a positive impact for doctors and healthcare systems.

We’re committed about reducing the demand for training and follow-up visits but also about optimizing drugs’ effectivenes generating relevant savings for national healthcare systems.

Respira's device increases compliance and effectiveness of any spray drug

A preliminary “in-vitro” study has certified that the device optimizes drug administration by generating a measurable positive effect on deposition in the distal parts of the lung-simulating impactor.

We want to become the ideal partner for patients, doctors, and healthcare systems improving therapeutic adherence by producing a relevant increase in patients’ quality of life and generating a positive impact for doctors and healthcare systems.

We’re committed about reducing the demand for training and follow-up visits but also about optimizing drugs’ effectivenes generating relevant savings for national healthcare systems.

Home Facebook Instagram Linkedin

We'll generate precious medical data about real patient's behaviours

The medical device produced by Respira will collect usage data from the user, and its breath activation system ensures that each drug delivery corresponds to an effective inhalation from the user/patient.

All monitoring solutions currently available on the market (trackers and dispensing counters) generate statistics without any medical value because they can monitor only the use of the inhalers but they are unable to measure their effective medical usage.

The company will collect and distribute valuable medical stats that will measure patients’ real drug inhalations.

We'll generate precious medical data about real patient's behaviours

The medical device produced by Respira will collect usage data from the user, and its breath activation system ensures that each drug delivery corresponds to an effective inhalation from the user/patient.

All monitoring solutions currently available on the market (trackers and dispensing counters) generate statistics without any medical value because they can monitor only the use of the inhalers but they are unable to measure their effective medical usage.

The company will collect and distribute valuable medical stats that will measure patients’ real drug inhalations.
Home Facebook Instagram Linkedin

Our Mission

Improve the health of persons who have respiratory disorders: only one out of every ten patients using a metered dosage inhaler completes all critical steps successfully, resulting in low treatment adherence and bad results for both patients and healthcare systems.

This condition is primarily due to the lack of several essential abilities required of pMDI inhalers, such as good hand-breath coordination, a faultless inhalation technique, and a reasonable inspiration flow. Unfortunately, these abilities are not common among the two main groups of asthma and COPD patients (children and the elderly), and this scenario necessitates technical assistance. Our solutions, which include an assisted inhalation device and a collection of medical statistics, are intended to help individuals enhance drug administration and give a smart method for monitoring daily treatment adherence via smartphone. We are dedicated to significantly improving the health of everyone suffering from a respiratory condition by delivering unique non-pharmaceutical alternatives.

Our Mission

Improve the health of persons who have respiratory disorders: only one out of every ten patients using a metered dosage inhaler completes all critical steps successfully, resulting in low treatment adherence and bad results for both patients and healthcare systems.

This condition is primarily due to the lack of several essential abilities required of pMDI inhalers, such as good hand-breath coordination, a faultless inhalation technique, and a reasonable inspiration flow. Unfortunately, these abilities are not common among the two main groups of asthma and COPD patients (children and the elderly), and this scenario necessitates technical assistance. Our solutions, which include an assisted inhalation device and a collection of medical statistics, are intended to help individuals enhance drug administration and give a smart method for monitoring daily treatment adherence via smartphone. We are dedicated to significantly improving the health of everyone suffering from a respiratory condition by delivering unique non-pharmaceutical alternatives.

Home Facebook Instagram Linkedin

Our vision

Enhance compliance and well-being of people generating substantial savings for healthcare systems: Respira is committed to generating additional value for all healthcare stakeholders: from patients to doctors and governments.

Improving therapeutic adherence produces a relevant increase in patients’ quality of life but it already generates a positive impact on doctors reducing the demand for follow-up visits, and it causes a reduction in drug prescriptions with significant savings for national healthcare systems.We want to fill that market niche and become the perfect complementary partner for patients, doctors, and healthcare systems. The current pharmaceutical market is full of extremely performing molecules, but there is an incomprehensible lack of technological solutions for ensuring perfect lung delivery.

Home Facebook Instagram Linkedin

Our vision

Enhance compliance and well-being of people generating substantial savings for healthcare systems: Respira is committed to generating additional value for all healthcare stakeholders: from patients to doctors and governments.

Improving therapeutic adherence produces a relevant increase in patients’ quality of life but it already generates a positive impact on doctors reducing the demand for follow-up visits, and it causes a reduction in drug prescriptions with significant savings for national healthcare systems.We want to fill that market niche and become the perfect complementary partner for patients, doctors, and healthcare systems. The current pharmaceutical market is full of extremely performing molecules, but there is an incomprehensible lack of technological solutions for ensuring perfect lung delivery.

Home Facebook Instagram Linkedin

Respira's Assisted Inhalation Device

The company has designed an innovative medical device that solves the problem of poor hand-breath coordination optimizing drug administration and increasing pulmonary deposition.

The device looks like a shell in which the user places a pre-dosed spray inhaler (pMDI) obtaining immediate automation at the breath: when he inhales through the mouthpiece the device detects his inspiratory act, and it instantly delivers an optimized dose of a drug through an electromechanical compression system if they can. This compression technology ensures that the medicine is completely vaporized at the peak of the patient’s inspiratory flow, boosting the drug’s pulmonary deposition.

Home Facebook Instagram Linkedin

Respira's Assisted Inhalation Device

The company has designed an innovative medical device that solves the problem of poor hand-breath coordination optimizing drug administration and increasing pulmonary deposition.

The device looks like a shell in which the user places a pre-dosed spray inhaler (pMDI) obtaining immediate automation at the breath: when he inhales through the mouthpiece the device detects his inspiratory act, and it instantly delivers an optimized dose of a drug through an electromechanical compression system if they can. This compression technology ensures that the medicine is completely vaporized at the peak of the patient’s inspiratory flow, boosting the drug’s pulmonary deposition.
Home Facebook Instagram Linkedin

Respira's Medical Data

The company will collect and distribute valuable medical stats that will measure patients’ real drug inhalations. The medical device produced by Respira will collect usage data from the user, and its breath activation system ensures that each drug delivery corresponds to an effective inhalation from the user/patient

All monitoring solutions currently available on the market (trackers and dispensing counters) generate statistics without any medical value because they can monitor only the use of the inhalers but they are unable to measure their effective medical usage. Respira’s mission is to gather, develop, and share medical statistics that will enable proper monitoring of any spray therapy’s compliance, as well as the measurement of the true benefit gained from each medicine.

Home Facebook Instagram Linkedin

Respira's Medical Data

The company will collect and distribute valuable medical stats that will measure patients’ real drug inhalations. The medical device produced by Respira will collect usage data from the user, and its breath activation system ensures that each drug delivery corresponds to an effective inhalation from the user/patient

All monitoring solutions currently available on the market (trackers and dispensing counters) generate statistics without any medical value because they can monitor only the use of the inhalers but they are unable to measure their effective medical usage. Respira’s mission is to gather, develop, and share medical statistics that will enable proper monitoring of any spray therapy’s compliance, as well as the measurement of the true benefit gained from each medicine.

Home Facebook Instagram Linkedin

Alessandro Guglietta

Finance manager with more than ten years of experience in leading pharmaceutical companies gaining incremental financial responsibilities in strategic management

During the first year of the pandemic, he decided to use his knowledge to build his answer to a widespread market need: the low compliance of people who use manual spray inhalers. He built the prototype using leftover material, and then he shared the result with a pulmonologist friend obtaining enthusiastic feedback that induced him to continue the project. Thirty months after the prototype the “Respira project” has been defined became an innovative startup ready to create a new and revolutionary medical device to support the intake of spray therapies.

Home Facebook Instagram Linkedin

Alessandro Guglietta

Finance manager with more than ten years of experience in leading pharmaceutical companies gaining incremental financial responsibilities in strategic management

During the first year of the pandemic, he decided to use his knowledge to build his answer to a widespread market need: the low compliance of people who use manual spray inhalers. He built the prototype using leftover material, and then he shared the result with a pulmonologist friend obtaining enthusiastic feedback that induced him to continue the project. Thirty months after the prototype the “Respira project” has been defined became an innovative startup ready to create a new and revolutionary medical device to support the intake of spray therapies.

Linkedin

Fabio Penzo

Entrepreneur with two successful exits, business angel, mentor, and expert in company development

Fabio Penzo is a diverse expert who has used a constructive engineering approach to find novel solutions in a variety of technology disciplines. His expertise with Floome is a valuable advantage for Respira, and he will follow some of its steps in search of a similar success story.

Home Facebook Instagram Linkedin

Fabio Penzo

Entrepreneur with two successful exits, business angel, mentor, and expert in company development

Fabio Penzo is a diverse expert who has used a constructive engineering approach to find novel solutions in a variety of technology disciplines. His expertise with Floome is a valuable advantage for Respira, and he will follow some of its steps in search of a similar success story.

Linkedin

Filippo Fassio

A surgeon with a Ph.D. in clinical and experimental medicine with specialization in allergology and clinical immunology

He’s an expert in medical-scientific dissemination that developed a well-known Facebook sharing content about allergies. He is serving as a scientific referent for an association of allergic patients (Centro Studi Allergie ETS) and he’s one of the web editors of the European Academy of Allergy and Clinical Immunology (a scientific society with over ten thousand associated professionals).

Home Facebook Instagram Linkedin

Filippo Fassio

A surgeon with a Ph.D. in clinical and experimental medicine with specialization in allergology and clinical immunology

He’s an expert in medical-scientific dissemination that developed a well-known Facebook sharing content about allergies. He is serving as a scientific referent for an association of allergic patients (Centro Studi Allergie ETS) and he’s one of the web editors of the European Academy of Allergy and Clinical Immunology (a scientific society with over ten thousand associated professionals).

Home Facebook Linkedin

Valerio Cometti + V12design

Valerio Cometti is the founder of the studio and he currently leads the creative team. He has promoted a strong connection between manufacturing processes and feasibility issues contributing to the development of an innovative approach to preserving the creative spirit during the entire industrial development of each product. Marco Generali is the co-founder of the company, and he currently leads the business development department. He combines an engineering background with significant mentorship skills, and he is a precious ally in designing the company’s growth path.
V12 Design is one of the most famous design studios in Italy, it was founded in 2005 and worked with some of the most prestigious international companies in more than 20 different countries. In recent years he has accompanied many companies in their growth path, assisting them in the strategic choices necessary to define a long-term path. The smooth integration between design and engineering combined with a deep knowledge of manufacturing processes always brings additional value for customers through the reduction of project reworks and errors during the entire product development phase.
Home Facebook Instagram Linkedin

Parametric Design

Marco Pettenella is the co-founder of the company, and he currently manages the business development department with his thirty years of experience gained in multinational companies dealing with a large level of complexity.  Luca Loretti is an expert bio-engineer with relevant expertise in designing technical applications for medical devices.

For over twenty years, Parametric Design has supported hundreds of companies to implement optimized product development processes through powerful, innovative, and adaptable software. The company offers four types of complementary consultancy services: design, industrialization, simulation, and management of business processes.

Home Linkedin Facebook

Swhard

Alfonso Mantero is the co-founder of Swhard and founder of LogOil (IoT area), holding the position of CEO for both companies. Egon Carusi is the co-founder of Swhard, and he currently holds the position of head of the technical area. Igor Ingegnosi is a project manager with an extensive experience in technology companies (Movendo, Ericcson, Marconi).

SWHARD is an innovative company founded in 2012 which proposes itself as an external R&D department. The company provides a complete set of solutions from problem analysis to production through system design, engineering, prototyping, testing, and data analysis. It extends its software skills from low-power firmware for IoT devices to the development of Linux drivers and kernels for real-time embedded systems, from product design to component selection, from layout to mechanical drafting.

Home Linkedin

Vispe Medical Device Consulting

Vito Santoro is the company’s founder and director, and he has spent his whole international career in the regulatory field, interacting with over 750 German enterprises. His significant experience has enabled him to effectively get all medical device certifications, with a special emphasis on the European and American markets.

The plan included the main activities foreseen for the patent development phase: design, industrial engineering, electrical engineering, and certification. The participation application is currently under review and its complete acceptance would grant the company a non-repayable loan of 140,000 euros.

Home Facebook Instagram Linkedin

Vispe Medical Device Consulting

Vito Santoro is the company’s founder and director, and he has spent his whole international career in the regulatory field, interacting with over 750 German enterprises. His significant experience has enabled him to effectively get all medical device certifications, with a special emphasis on the European and American markets.

The plan included the main activities foreseen for the patent development phase: design, industrial engineering, electrical engineering, and certification. The participation application is currently under review and its complete acceptance would grant the company a non-repayable loan of 140,000 euros.

Home Linkedin

Respira's company creation

Respira is a firm situated in Parma (Italy) that was created on September 16, 2022

The company has a patent for an industrial invention involving a “medical inhaler activated through breath,” and the Parma Chamber of Commerce has acknowledged it as an innovative startup.

Participation in "Patent+" tender

In September 2022, the company has been admitted to the “Patent plus” tender issued by the Italian Ministry of Economic Development and presented a plan to enhance its patent worth 220,000 euros.

The plan included the main activities foreseen for the patent development phase: design, industrial engineering, electrical engineering, and certification. The participation application is currently under review and its complete acceptance would grant the company a non-repayable loan of 140,000 euros.

In vitro study at Parma University

In collaboration with the University of Parma, the company conducted an in vitro study: Professor Ruggero Bettini, Director of the Interdepartmental Center for the Innovation of Health Products, conducted a deposition study by measuring the actual capacity of the current prototype to positively influence the administration of a spray drug.

The study was conducted using a cascade impactor that simulates the structure of the human lung, and it confirmed that device-assisted drug delivery resulted in a reduction in the diameter of the drug’s particles, a significant increase in the respirable fraction, and a higher drug deposition at the distal level. As a result, the device has demonstrated the capacity to optimize drug administration by generating a measurable positive effect on deposition in the distal parts of the lung-simulating impactor: these are encouraging results that will be investigated further in the coming months.